Published in J Immunol on July 28, 2017
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 24.54
Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med (2009) 10.01
Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature (2009) 6.67
Dendritic cells in intestinal immune regulation. Nat Rev Immunol (2008) 4.20
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature (2015) 3.86
Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell (2014) 3.40
Generation of murine dendritic cells from flt3-ligand-supplemented bone marrow cultures. Blood (2000) 2.45
The interaction of versican with its binding partners. Cell Res (2005) 2.22
Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell (2014) 2.00
Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition. Immunity (2016) 1.69
Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. Cell Rep (2015) 1.67
Selective and efficient generation of functional Batf3-dependent CD103+ dendritic cells from mouse bone marrow. Blood (2014) 1.60
Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses. Cell (2017) 1.59
Myeloid progenitor cells in the premetastatic lung promote metastases by inducing mesenchymal to epithelial transition. Cancer Res (2012) 1.57
Type I interferons in anticancer immunity. Nat Rev Immunol (2015) 1.57
Innate immune recognition of cancer. Annu Rev Immunol (2015) 1.52
The biological role and regulation of versican levels in cancer. Cancer Metastasis Rev (2009) 1.51
ADAMTS1, CRABP1, and NR3C1 identified as epigenetically deregulated genes in colorectal tumorigenesis. Cell Oncol (2006) 1.48
Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. Cancer Cell (2017) 1.40
Identification of cDC1- and cDC2-committed DC progenitors reveals early lineage priming at the common DC progenitor stage in the bone marrow. Nat Immunol (2015) 1.23
Regulation of the immune system by the resident intestinal bacteria. Gastroenterology (2014) 1.19
The expression and regulation of ADAMTS-1, -4, -5, -9, and -15, and TIMP-3 by TGFbeta1 in prostate cells: relevance to the accumulation of versican. Prostate (2005) 1.13
Versican and the control of inflammation. Matrix Biol (2014) 1.13
The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment. Semin Oncol (2015) 1.06
TPL2 kinase regulates the inflammatory milieu of the myeloma niche. Blood (2014) 0.97
The multiple, complex roles of versican and its proteolytic turnover by ADAMTS proteases during embryogenesis. Matrix Biol (2014) 0.95
Roles of versican in cancer biology--tumorigenesis, progression and metastasis. Histol Histopathol (2013) 0.95
Tumor-Elicited Inflammation and Colorectal Cancer. Adv Cancer Res (2015) 0.92
Versican expression is associated with tumor-infiltrating CD8-positive T cells and infiltration depth in cervical cancer. Mod Pathol (2010) 0.91
Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells. Cancer Discov (2015) 0.88
Opportunities for immunotherapy in microsatellite instable colorectal cancer. Cancer Immunol Immunother (2016) 0.86
Inflammation amplification by Versican: the first mediator. Int J Mol Sci (2012) 0.85
Epidemiology of colorectal cancer. Int J Mol Epidemiol Genet (2016) 0.83
The Tumor Macroenvironment: Cancer-Promoting Networks Beyond Tumor Beds. Adv Cancer Res (2015) 0.83
Microbiota modulation of myeloid cells in cancer therapy. Cancer Immunol Res (2015) 0.82
Toll-like Receptor 2 Activation Promotes Tumor Dendritic Cell Dysfunction by Regulating IL-6 and IL-10 Receptor Signaling. Cell Rep (2015) 0.81
IRF8 Transcription Factor Controls Survival and Function of Terminally Differentiated Conventional and Plasmacytoid Dendritic Cells, Respectively. Immunity (2016) 0.81
Bioactive extracellular matrix fragments in lung health and disease. J Clin Invest (2016) 0.80
The emerging role of immunotherapy in colorectal cancer. Ann Transl Med (2016) 0.80
Tumor and Host Factors Controlling Antitumor Immunity and Efficacy of Cancer Immunotherapy. Adv Immunol (2016) 0.78
Isolation and purification of versican and analysis of versican proteolysis. Methods Mol Biol (2015) 0.78
The tumour microenvironment harbours ontogenically distinct dendritic cell populations with opposing effects on tumour immunity. Nat Commun (2016) 0.78
Immunoregulatory roles of versican proteolysis in the myeloma microenvironment. Blood (2016) 0.78
Immunotherapy for prostate cancer: False promises or true hope? Cancer (2016) 0.78
Fine-Tuning Cancer Immunotherapy: Optimizing the Gut Microbiome. Cancer Res (2016) 0.77
Biomarkers for immune therapy in colorectal cancer: mismatch-repair deficiency and others. J Gastrointest Oncol (2016) 0.77
Extracellular matrix and the myeloid-in-myeloma compartment: balancing tolerogenic and immunogenic inflammation in the myeloma niche. J Leukoc Biol (2017) 0.77
Towards integrating extracellular matrix and immunological pathways. Cytokine (2017) 0.76
ADAMTS5 Is a Critical Regulator of Virus-Specific T Cell Immunity. PLoS Biol (2016) 0.75